BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

TxCell Announces Positive Preliminary Results from the Phase I/IIa Clinical Trial of OvaSave(R) in Crohn's Disease


4/30/2010 1:24:56 PM

Valbonne, France, April 29, 2010 – TxCell SA, a French biotechnology company developing autologous cell-based therapies using Type 1 T-regulatory lymphocytes (Tr1) for the treatment of chronic inflammatory and autoimmune diseases, today announced positive preliminary results from the ongoing Phase I/IIa clinical trial regarding OvaSave(R), an investigational new drug, in patients with severe and refractory Crohn’s disease. Preliminary results from the study showed that OvaSave(R) is well-tolerated and that an encouraging efficacy signal has been observed.

The announcement comes as TxCell is planning a Series C financing round in the near future as part of its clinical development program. This will focus on confirming these positive results and providing a human proof of concept for inflammatory bowel diseases and rheumatoid arthritis.

“The positive signal observed in this study is an excellent start to the process of demonstrating the clinical benefit of our cell based therapy,” said Frederic Hammel, Chief Executive Officer at TxCell. “It also creates a real hope for severe refractory patients.”

Crohn’s disease is a chronic, often disabling disorder with a significant unmet medical need since existing treatments still do not provide a complete answer. OvaSave(R) is a new advanced medicinal product in clinical development based on autologous Tr1 cells. It represents a potential new treatment opportunity for patients with severe Crohn’s disease who do not respond to existing conventional treatments.

These initial results mean that TxCell can proceed with designing a Phase IIb trial. "The Phase I/IIa trial was planned as a dose escalation study for a first injection in Man,” said Miguel Forte, TxCell Chief Medical Officer. “The preliminary evidence of tolerability and positive efficacy signal detected in this study is providing us with relevant data to select the doses and regimens for the design of an European Phase IIb randomized controlled confirmatory trial in Crohn’s disease, as well as for two exploratory, open label Phase I/IIa trials in Rheumatoid Arthritis and in Ulcerative Colitis.”

TxCell will attend BIO Chicago, USA, booth 3712, France Pavillon, May 3-6.

About the Phase I/IIa clinical trial

The ongoing 12 week, multicenter, open label, uncontrolled and dose-escalation Phase I/IIa study is designed to evaluate the safety and efficacy of OvaSave(R) therapy in patients with severe and relapsing Crohn’s disease. The product is injected intravenously as a single administration to patients with chronic active Crohn's disease. Six sites in France enrolled patients distributed into four different cohorts with doses of 106, 107, 108 and 109 cells.

About TxCell

TxCell SA was spun out of Inserm (France's National Institute for Health and Medical Research) in 2001. The company develops an innovative immunomodulating approach, using living cells to regenerate the equilibrium of the immune system in chronic inflammatory and autoimmune diseases. TxCell products are injectable cell suspensions of therapeutic autologous antigen specific Tr1 clones.

The Afssaps (the French Agency for Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn's disease. The final results of this Phase I/IIa are expected by the end of 2010. The firm is based in the Sophia Antipolis technology park, near Nice in southern France.

For more information, please visit http://www.txcell.com

Read at BioSpace.com

TxCell
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->